Saturday, July 11, 2026

Drug profile · INN

phenmetrazine hydrochloride

phenmetrazine hydrochloride (PRELUDIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — phenmetrazine hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

phenmetrazine hydrochloride (PRELUDIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN phenmetrazine hydrochloride
Brand PRELUDIN
Mechanism Dopamine transporter inhibitor
Target Sodium-dependent dopamine transporter
Route ORAL
Formulation TABLET

Mechanism of action

Dopamine transporter inhibitor

Primary target: Sodium-dependent dopamine transporter

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. amphetamine adipate Dopamine transporter releasing agent
  2. amphetamine aspartate Norepinephrine transporter releasing agent
  3. amphetamine sulfate Norepinephrine transporter releasing agent
  4. armodafinil Dopamine transporter inhibitor
  5. bupropion hydrochloride Dopamine transporter inhibitor
  6. dexmethylphenidate hydrochloride Norepinephrine transporter inhibitor

Frequently asked questions

What is phenmetrazine hydrochloride?

phenmetrazine hydrochloride (PRELUDIN) is a dopamine transporter inhibitor. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for phenmetrazine hydrochloride?

PRELUDIN is a marketed brand name for phenmetrazine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of phenmetrazine hydrochloride?

phenmetrazine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.